Endometrial Cancer   

Do you offer observation for POLE mutated tumors?

Are there certain patient subgroups for whom you would use the IO+PARPi? Is there data from DUO-E regarding BRCA status and its potential impact on ...

If yes, would you apply this broadly or reserve the addition of IO to chemotherapy for patients with high-risk histologies (e.g., carcinosarcoma) or o...

Does your decision depend on MMR status? Would you use the same approach for neoadjuvant treatment?In light of relevant trials including RUBY, GY018, ...

DUO-E, GY-018, and RUBY included patients with stage III and IV endometrial cancer WITH measurable disease.Would your decision change based on the mis...

Are there patients for whom you would still reserve IO for salvage/recurrent setting (eg IO + lenvatinib)? Would you base this on MMR status or other ...

What would you recommend for a patient in their 60s with stage IB grade 1 endometrial cancer without LVSI? How would this differ for a patient with st...

Do you proceed with sequential, concurrent, or sandwich treatment?

How will you translate treatment recommendations from older studies to the new staging system?

Does the presence of parametrial or cervical involvement impact your decision? How do you sequence treatment modalities?

This case involves an impressive ‘high volume’ vaginal recurrence and patient was not originally planned for adjuvant therapy. Concerned t...

Considering the ASTRO guidelines recommend against systemic therapy for patients with FIGO stage I-II endometrioid adenocarcinoma, would your recommen...

Please comment on toxicity profiles and the insufficient evidence regarding overall survival.

If you do not use the PORTEC-3 regimen for p53 mutated IA endometrial cancer, what specific protocol or combination of chemotherapy and radiation ther...

How do you take into account pathologic factors like %clear cell histology, myometrial invasion, and LVSI?  

How does your approach differ for patients under age 60, between 60-70, and over age 70?

How does histology and/or molecular testing change your approach? How does the length of the disease free interval change your approach?

In what situations would you use a neuroendocrine chemotherapy regimen over carboplatin+paclitaxel?

Is there a role for using pembrolizumab alone in microsatellite stable endometrial cancer if patients are unable to tolerate lenvatinib?

Are there specific clinical or social scenarios that would preclude the use of this treatment?

In the KEYNOTE-775 study, what was the proportion of patients who had a recurrence free interval ≥1 year from platinum-based cytotoxic chemotherapy...

Are there any planned trials to compare lenvatinib + pembrolizumab and platinum-based cytotoxic chemotherapy for advanced or recurrent endometrial can...

Does your approach to the number of cycles vary based on plan to include radiation therapy or presence of certain histopathologic features?

Anecdotally, I have seen more serious IRAEs in patients I'm treating with this regimen than anticipated. Is there higher risk with this drug combinati...

Are there certain patient or disease related factors that would lead you to incorporate lenvatinib + pembrolizumab earlier?

And if the tumor is MSI-H, does that alter your thoughts?

How does the presence of specific mutations affect your adjuvant treatment planning or patient counseling? Given POLE mutation status can currently o...

Given data from metastatic breast cancer trials that show benefit with continuing trastuzumab despite progression.

Do you stop therapy at 2 years or continue until progression of disease?

Patient has tolerated combination therapy well to date.

If patient meets high intermediate risk criteria, would you consider chemotherapy in addition to radiation?

Does not technically meet high intermediate risk criteria.

The patient has a history of pelvic radiation and progressed through first line carboplatin/taxol. She has had a partial response to pembro/lenvatinib...

Does residual grade 1-2 neuropathy from Taxol/ carbo 10 years ago affect your recommendation?

Ie for patients who are inoperable due to comorbidities?

Since no data exists or is pending, and the two disease processes are similar, should we consider PARP inhibition in this setting? This is assumi...

 No adjuvant treatment was given upfront

The NCCN recommends either systemic therapy + brachytherapy or pelvic RT + brachy or brachy alone or observation. How do you decide among these option...

Given the recent press release regarding the update on the phase 3 soft tissue sarcoma study of LARTRUVO (olaratumab) showing no benefit to the combin...

Would you approach this situation as synchronous primaries (eg. FIGO IA in both) or as a locally advanced endometrial cancer (FIGO IIIA)? What adjuva...